´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG Symposium&Workshop-Cervix, Vulva, Vagina TSC Workshop : 2024-02-24
±³À°ÀÏÀÚ : 2024-02-24
±³À°Àå¼Ò : °í·Á´ëÇб³ À¯±¤»çȦ
±³À°ÁÖÁ¦ : KGOG Symposium&Workshop-Cervix, Vulva, Vagina TSC Workshop
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÇý¼÷
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ : kelly.kim1436@gmail.com
±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 5ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 09:00~09:15 Gynecologic Oncology Group Foundation ¹é¹ÎÇö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 09:15~09:30 Gynecologic Cancer InterGroup ÀÌ»êÈñ(¿øÁֱ⵶¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 09:30~09:45 European Network of Gynaecological Oncological Trial groups (ENGOT) ÀÌÁöÇö(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 09:45~10:00 East Asian Gynecologic Oncology Trial Group (EAGOT)¡¡& Asia-Pacific Gynecologic Oncology Trials Group (APGOT) ÇÑ°æÈñ(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 10:20~10:35 Exploring Minimally Invasive Surgical Approaches in Cervical cancer Trials ±è¸í¼±(¼ººó¼¾Æ®º´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 10:35~10:50 Advancements in Low-Risk Early-Stage Cervical Cancer Trials ±èÀºÅÃ(°í½Å´ëÇб³º¹À½º´¿ø)
Åä·Ð 02¿ù 24ÀÏ À¯±¤»çȦ 10:50~11:05 Panel discussion including ROCC trial ¼Û¹ÎÁ¾±è±âµ¿ÀÓ¸íö(¿©Àǵµ¼º¸ðº´¿øºÐ´ç¼¿ï´ëÇб³º´¿ø±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 11:50~12:10 Pembrolizumab in Cervical Cancer: KEYNOTE-826 Insights & Sub-Analyses at ASCO, ESGO, ASGO 2023 À̸¶¸®¾Æ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 13:10~13:25 KGOG 1047-Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICr: A phase III, randomized controlled clinical trial (DEBULK Trial) ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 13:25~13:40 KGOG 1036-Prospective-specimen-collection and retrospective blinded-evaluation study of HPV viral load to improve cervical cancer screening ±è¹ÎÁ¤(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 13:40~13:55 KGOG 1037-Retrospective-Impact of metformin of medication on survival outcome of cervical cancer ¹é¹ÎÇö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 13:55~14:10 KRC-01-C01-A Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 Intratumoral Injection Combined with Radiotherapy in Patients with Locally Advanced Cervical Cancer Á¶¿¬¾Æ(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 14:10~14:30 Revolutionizing Oncology : The Paradigm of Cancer Immunotherapy À̼öÁ¤(°æºÏ´ëÇб³Ä¥°îº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 14:30~14:50 Precision Therapeutics : Navigating the Landscape of Antibody Drug Conjugates ±è¼±¿µ(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 02¿ù 24ÀÏ À¯±¤»çȦ 14:50~15:10 Panel discussion ¹Ú¿µÇÑÃÖöÈƱè°Ç¹Î(ÇѸ²´ë¼º½Éº´¿ø»ï¼º¼¿ïº´¿ø¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 15:30~15:45 KGOG 1028S-Radiotherapy versus Observation in intermediate risk patients after Radical hysterectomy for early cervical cancer : Ancillary analysis of a Korean Gynecologic Group Study ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 15:45~16:00 KGOG 1046-Adjuvant Chemotherapy Versus Radiotherapy For Postoperative Cervical Cancer : a phase 3 trial ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 16:00~16:15 KGOG 1044-Feasibility of HPV DNA and vaginal infectious disease detection in mail-delivered self obtained vaginal sample obtained by G+KitⓇ ±è¹®È«(¿øÀڷº´¿ø)
±³À°½Ã°£ 02¿ù 24ÀÏ À¯±¤»çȦ 16:15~16:30 KGOG 1038-Phase II study of Belotecan monotherapy in patients with recurrent of persistent cervical cancer À̱¤¹ü(°¡ÃµÀÇ´ë±æº´¿ø)